Danielle J. Beetler

Danielle J. Beetler

Auto-generated profile, based on publicly available information

Danielle J. Beetler

Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2023 in Small
Verified
Journal Article
Open access
DBDanielle J. Beetler
Danielle J. Beetler
KBKatelyn Ann Bruno
Katelyn Ann Bruno
MWMolly M. Watkins
Molly M. Watkins
VXVivian Xu
Vivian Xu
ICIsha Chekuri
Isha Chekuri
DFDeLisa Fairweather
DeLisa Fairweather
Patients with viral myocarditis are at risk of sudden death and may progress to dilated cardiomyopathy (DCM). Currently, no disease‐specific therapies exist to treat viral myocarditis. Here it is examined whether reconstituted, lyophilized extracellular vesicles (EVs) from platelets from healthy men and women reduce acute or chronic myocarditis in male mice. Human‐platelet‐derived EVs (PEV) do not cause toxicity, damage, or inflammation in naïve mice. PEV administered during the innate immune response significantly reduces myocarditis with fewer epidermal growth factor (EGF)‐like module‐containing mucin‐like hormone receptor‐like 1 (F4/80) macrophages, T cells (cluster of differentiation molecules 4 and 8, CD4 and CD8), and mast cells, and improved cardiac function. Innate immune mediators known to increase myocarditis are decreased by innate PEV treatment including Toll‐like receptor (TLR)4 and complement. PEV also significantly reduces perivascular fibrosis and remodeling including interleukin 1 beta (IL‐1β), transforming growth factor‐beta 1, matrix metalloproteinase, collagen genes, and mast cell degranulation. PEV given at days 7–9 after infection reduces myocarditis and improves cardiac function. MicroRNA (miR) sequencing reveals that PEV contains miRs that decrease viral replication, TLR4 signaling, and T‐cell activation. These data show that EVs from the platelets of healthy individuals can significantly reduce myocarditis and improve cardiac function.

17 April 2023 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
KMKayleah M. Meneses
Kayleah M. Meneses
PPPrita Pandya
Prita Pandya
JLJennifer A. Lindemann
Jennifer A. Lindemann
DADania S. Al-Qasrawi
Dania S. Al-Qasrawi
RARyan A. Argo
Ryan A. Argo
VJVerline Justilien
Verline Justilien
Cancer stem cells (CSC) within non–small cell lung carcinoma (NSCLC) tumors drive NSCLC progression, metastasis, relapse, and intrinsic chemoresistance. Understanding the mechanisms that support the malignant phenotypes of NSCLC CSCs may provide insights for improved NSCLC therapeutic interventions. Here, we report that expression of RAB27B, a small GTPase, is significantly upregulated in NSCLC CSCs when compared with bulk cancer cells (BCC). Short hairpin RNA–mediated knockdown of RAB27B leads to a loss of stem cell marker gene expression and reduced NSCLC spheroid growth, clonal expansion, transformed growth, invasion, and tumorigenicity. We find that NSCLC CSCs secrete significantly more extracellular vesicles (EV) than BCCs, and that this is RAB27B-dependent. Furthermore, CSC-derived EVs, but not BCC-derived EVs, induce spheroid growth, clonal expansion, and invasion in BCCs. Finally, RAB27B is required for CSC-derived EV-induced stemness in BCCs. Taken together, our results indicate that RAB27B is required for maintenance of a highly tumorigenic, cancer-initiating, invasive stem-like cell population in NSCLC and RAB27B is involved in propagating EV-mediated communication from NSCLC CSCs to BCCs. Our findings further suggest that inhibition of RAB27B-dependent EV secretion may be a potential therapeutic strategy for NSCLC.Significance: Expression of RAB27B in CSCs leads to elevated levels of EVs that mediate communication between CSCs and BCCs that maintains a stem-like phenotype in NSCLC cells.

26 November 2025 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
DBDanielle J. Beetler
Danielle J. Beetler
PGPresley Giresi
Presley Giresi
VXVivian Xu
Vivian Xu
EMElizabeth J. McCabe
Elizabeth J. McCabe
JFJessica J. Fliess
Jessica J. Fliess
DFDeLisa Fairweather
DeLisa Fairweather
Extracellular vesicles (EVs) are promising therapeutics for diseases associated with inflammation and tissue remodeling. However, a major limitation for th

17 April 2023
Verified
Other
Open access
PDF file
KMKayleah M. Meneses
Kayleah M. Meneses
PPPrita Pandya
Prita Pandya
JLJennifer A. Lindemann
Jennifer A. Lindemann
DADania S. Al-Qasrawi
Dania S. Al-Qasrawi
RARyan A. Argo
Ryan A. Argo
VJVerline Justilien
Verline Justilien
Supplementary Figure S3: RAB27B is required for NSCLC tumorigenicity in vivo

17 April 2023
Verified
Other
Open access
PDF file
KMKayleah M. Meneses
Kayleah M. Meneses
PPPrita Pandya
Prita Pandya
JLJennifer A. Lindemann
Jennifer A. Lindemann
DADania S. Al-Qasrawi
Dania S. Al-Qasrawi
RARyan A. Argo
Ryan A. Argo
VJVerline Justilien
Verline Justilien
Supplementary Figure S3: RAB27B is required for NSCLC tumorigenicity in vivo

17 April 2023
Verified
Other
Open access
PDF file
KMKayleah M. Meneses
Kayleah M. Meneses
PPPrita Pandya
Prita Pandya
JLJennifer A. Lindemann
Jennifer A. Lindemann
DADania S. Al-Qasrawi
Dania S. Al-Qasrawi
RARyan A. Argo
Ryan A. Argo
VJVerline Justilien
Verline Justilien
Supplementary Figure S1: RAB27B expression in CSC cultures